AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

As­traZeneca is part­ner­ing with Quell Ther­a­peu­tics to de­vel­op reg­u­la­to­ry T cell ther­a­pies for type 1 di­a­betes and in­flam­ma­to­ry bow­el dis­ease, join­ing the grow­ing move­ment of com­pa­nies and aca­d­e­m­ic groups de­vel­op­ing cell ther­a­pies for au­toim­mune dis­eases.…#quell #1diabetes #academic #royalties

Source: Reuters: Health - June 9, 2023 Category: Consumer Health News Source Type: news